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Novel internal regulators and 
candidate miRNAs within miR-
379/miR-656 miRNA cluster can 
alter cellular phenotype of human 
glioblastoma
Subhashree Nayak1, Meghali Aich2, Anupam Kumar3, Suman Sengupta4, Prajakta Bajad2, 
Parashar Dhapola5,6, Deepanjan Paul2,6, Kiran Narta2,6, Suvendu Purkrait7, Bharati Mehani2,6, 
Ashish Suri3, Debojyoti Chakraborty2,6, Arijit Mukhopadhyay2,6,8 & Chitra Sarkar1
Clustered miRNAs can affect functioning of downstream pathways due to possible coordinated 
function. We observed 78–88% of the miR-379/miR-656 cluster (C14MC) miRNAs were downregulated 
in three sub-types of diffuse gliomas, which was also corroborated with analysis from The Cancer 
Genome Atlas (TCGA) datasets. The miRNA expression levels decreased with increasing tumor grade, 
indicating this downregulation as an early event in gliomagenesis. Higher expression of the C14MC 
miRNAs significantly improved glioblastioma prognosis (Pearson’s r = 0.62; p < 3.08e-22). ENCODE 
meta-data analysis, followed by reporter assays validated existence of two novel internal regulators 
within C14MC. CRISPR activation of the most efficient internal regulator specifically induced members 
of the downstream miRNA sub-cluster and apoptosis in glioblastoma cells. Luciferase assays validated 
novel targets for miR-134 and miR-485-5p, two miRNAs from C14MC with the most number of target 
genes relevant for glioma. Overexpression of miR-134 and miR-485-5p in human glioblastoma cells 
suppressed invasion and proliferation, respectively. Furthermore, apoptosis was induced by both 
miRs, individually and in combination. The results emphasize the tumor suppressive role of C14MC in 
diffuse gliomas, and identifies two specific miRNAs with potential therapeutic value and towards better 
disease management and therapy.
Glioblastoma (GBM; WHO Grade IV1) has a very poor prognosis (median survival of 14 months2,3) after decades 
of research. This highlights the importance of novel alternative approach towards understanding and modulating 
the molecular pathophysiology of GBM. Regulatory molecules like transcription factors and non-coding RNAs 
(e.g. microRNAs) are higher order switches that can influence a large number of downstream targets. Deciphering 
the functioning of these switches will not only enhance our knowledge but also enable us to alter them towards 
translatable therapy. Understanding the local regulators of such higher order modulators (e.g. promoters of 
microRNAs) is thus a rational approach to empower such therapeutic potential.
MicroRNAs, the most-studied class of non-coding RNAs, play crucial role in several biological processes, 
from development to metabolism4–7. Several microRNAs have been proposed to possess prognostic importance 
for patient survival in gliomas8–10. Therapeutic interventions involving microRNAs are developing rapidly. A 
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single microRNA has multiple targets, thus they can be used to target entire pathways, although their delivery 
and stability still remain areas of active research. The role of large microRNA clusters in cancer biology is a rela-
tively new evolving area of research. Chromosome 14 microRNA cluster (C14MC) is located on human 14q32, 
a locus earlier reported to be unstable in gliomas11,12. This second largest miRNA cluster comprises of 73 mature 
miRNAs, spanning ~45 kb on 14q32.31, within the well-known DLK-DIO3 locus, and is placental mammal lin-
eage specific13. The prospect of local regulation within this large cluster is unknown, although the whole domain 
of DLK1-DIO3 is reported to be under hierarchical interaction via imprinting control regions14. C14MC has 
been implicated in various developmental pathways as well as found to be involved in several conditions, like 
neurogenesis5, neovascularization15 and metabolic transition during birth16. We have earlier reported overall 
down-regulation of this cluster in various cancers, including GBM17. Individual miRNAs from this cluster have 
been reported to be deregulated in leukemias18, esophageal squamous cell carcinoma19, etc. strengthening the 
speculation that these might be tumor suppressors in several cancer types. However, there are few cases where 
they are up-regulated, like in lung adenocarcinoma20.
Here we demonstrate the tumor suppressor potential of C14MC in GBMs, and evaluate the polycistronic 
nature of C14MC, hence, opening up new channels for modulating these non-coding elements, towards achieving 
a desired phenotype. We have assessed differential expression of these miRs in different grades of diffuse astro-
cytic tumors, which may have latent diagnostic or prognostic utility, when combined with other layers of clinical 
information. We have also identified key miRNAs from C14MC capable of reducing GBM tumorigenicity and 
hence may serve as potential future therapeutics.
Results
C14MC is downregulated in different grades of astrocytic tumors and higher miRNA expres-
sion is associated with better survival in GBM. Taqman Low Density Array (TLDA; ABI Inc.) was 
used to evaluate the expression profile of C14MC in diffuse astrocytic tumors. Profiling was done for 47 miRNAs 
from C14MC in 10 control samples, 35 GBMs (Glioblastoma; Grade IV), nine AAs (Anaplastic astrocytoma; 
Grade III), and 15 DAs (Diffuse astrocytoma; Grade II). The median number of miRNAs downregulated in GBM, 
AA and DA were 60%, 87% and 89%, respectively (one tailed Wilcoxon p < 0.05) [Fig. 1a; Supplemental file]. 
None of the miRs were seen to have significant up-regulation in any of the tumor types as compared to controls. 
Interestingly, 68% (32/47) miRs were downregulated in all the three tumor types studied, as calculated by 2−∆∆Ct 
method21.
We also used TCGA LGG datasets (Low Grade Glioma) for 148 samples (143 Patients and 5 controls) to 
validate our findings of lower grade astrocytomas on larger sample size. We identified 37 (95%) and 35 (90%) 
miRs to be significantly downregulated in both Grade II (n = 46) and III (n = 97) astrocytomas, respectively, as 
compared to controls even after Bonferroni correction [Fig. 1b], although, we could not find any significant dif-
ferentially expressing miRs between the two grades. TCGA data analysis revealed ~78% miRNAs downregulated 
from C14MC in GBM, which is in concordance with our earlier report17.
Interestingly, TCGA data (n = 350) revealed significant association of C14MC meta-expression with bet-
ter survival of GBM patients (Fig. 1c; Pearson’s r 0.62 after removing one outlier sample; p < 3.08e-22). When 
checked individually, higher expression of 63% (22/35) miRNAs from C14MC was associated with better prog-
nosis of GBM patients (Supplemental file). We found that four miRNAs (miR-134, miR-410, miR-409-3p and 
miR-494) from C14MC were significantly associated with IDH mutation. IDH-mutated GBM samples showed 
higher expression of these four miRNAs.
C14MC is not a single cistron: discovery of internal regulators. We next investigated the polycis-
tronic nature of C14MC for which integration of different layers of data, namely RNA-Seq and the presence of 
various histone marks, representative of transcriptionally active and repressed regions were used from ENCODE 
HUVEC and NHA datasets, respectively. It enabled better documentation of potential regulators in the ~60 kb 
region of C14MC (including ~20 kb upstream of the cluster), in view of the normal cell population. This would be 
representative of the physiological condition of the chromatin and the transcriptome contributed by this locus. 
Superimposition of epigenetic and transcriptomic data from ENCODE revealed four regions, having regulatory 
potential, in and around C14MC (Supplemental file). One of them, named Chromosome 14 Internal Promoter 3 
(C14-IP-3) showed enhanced activity compared to empty vector [Fig. 2A], both as promoter (>50 fold increased 
activity) and as enhancer (>15 fold increased activity).
Since this promoter showed consistently robust activity, in contrast to C14-IP-1, C14-IP-2 and C14-IP-4, we 
selected it for further downstream studies.
Positive induction of C14-IP-3 increases apoptosis in glioma. We next investigated the role of 
C14-IP-3 upon the apoptotic potential of glioma cells, using a CRISPR activation (CRISPRa) approach. For this, 
we used a catalytically inactive form of Cas9 (dCas9) fused with an activating domain (VP64) to selectively upreg-
ulate miRNAs from the C14-IP-3 sub-cluster. Using this approach, we could obtain between 1.2–2.5 fold upreg-
ulation of five out of eight sub-cluster miRNAs tested (Supplemental file). Interestingly, upon overexpression 
of these miRNAs, GBM cells showed ~3.6 fold and 2 fold increase respectively, in total and early apoptotic cell 
population [Fig. 2B; Supplemental file]. Taken together, this suggests the possibility of modulating the internal 
regulator in order to gain a desired expression pattern of the subcluster downstream – thus enabling a reversal of 
phenotype.
Key miRNAs from C14-IP-3 sub-cluster target EGFR, AKT, TP53 and RAF1 in GBM. We chose 
miR-134 and miR-485 from C14-IP-3 as they were predicted to target the highest number of targets in the “gli-
oma” pathway17. In this study these two miRNAs are mentioned as ‘Key’ miRNAs highlighting their possible 
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crucial roles in modulating biological outcomes. Consequently, we experimentally validated three out of four 
predicted downstream targets of these miRNAs, namely EGFR, TP53 and RAF1 – all known for their importance 
in glioma biology (Fig. 3A,B).
EGFR and RAF1 are novel targets of miR-134, which were successfully validated by luciferase assay. 
Additionally, we identified TP53 as a novel target of miR-485-5p, and validated it. However, we could not find 
positive interaction of CDK6 with miR-485-5p.
We randomly selected four additional genes (AKT2, AKT3 GRB2 and MMP2) from the “glioma” pathway, 
other than the validated targets of the key miRNAs.to check for downstream effect of miRNA overexpression. Five 
out of seven genes tested showed downregulation at the RNA level upon miR-134 overexpression (EGFR, RAF1, 
AKT2, TP53 and MMP2), whereas, two (MMP2 and RAF1) shared similar fate after miR-485 overexpression 
[Supplemental file]. EGFR, AKT, FAK and TP53 were also checked at protein level upon miRNA overexpression 
[Supplemental file]. The protein levels of EGFR and AKT showed about 10% decrease upon overexpression of 
both the miRNAs, whereas, TP53 showed ~8% decrease upon miR-485-5p overexpression. Interestingly, the most 
dramatic decrease (~75%) was seen in pAKT levels upon miR-485-5p overexpression.
MiR-134 overexpression decreases GBM cell invasion. Matrigel assay consistently revealed an aver-
age of ~30% decrease in cell invasion, after 48 hours of overexpression of miR-134 in U87-MG cells, compared 
to scrambled oligo transfection. We also found minimal decreased invasion in miR-485-5p transfected cells, 
but the data remained inconclusive. Cumulative effect of the miRNAs was also checked, using an equimolar 
Figure 1. Downregulation of C14MC in gliomas. (a) Downregulation of C14MC in gliomas (TLDA data). 
X-axis shows the group of samples; Grade II (Diffuse astrocytoma; n = 15), Grade III (Anaplastic astrocytoma; 
n = 9), Grade IV (Glioblastoma; n = 35) and controls (n = 10). Y-axis represents relative expression (delta Ct 
values). Median expression value of each sample group is represented in the box-plot. (b) (A) Downregulation 
of C14MC in gliomas (TCGA small RNA sequencing data). X-axis shows the group of samples; Grade II 
(Diffuse astrocytoma; n = 46), Grade III (Anaplastic astrocytoma; n = 97) and controls (n = 5). Y-axis represents 
relative expression (log transformed). Median expression value of each sample group is represented in the 
box-plot. (B) Downregulation of C14MC in gliomas (TCGA microarray data). X-axis shows the group of 
samples; Grade IV (Glioblastoma; n = 505) and controls (n = 10). Y-axis represents relative expression (lowess 
normalised). Median expression value of each sample group is represented in the box-plot. (c) Moderate 
association of C14MC expression with survival of GBM patients. X-axis represents meta-expression, derived 
from principal component 1 (extracted from Z-score values of Fold change for each miR across all GBM 
samples). Y-axis shows survival in days. The association was tested using Pearson’s test, after removing one 
outlier sample.
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mixture of both the miRs, which interestingly resulted in ~50% decrease in invasiveness of U87MG cells [Fig. 4; 
Supplemental file].
MiR-485-5p overexpression blocks GBM cell proliferation. The effect of overexpression of both the 
miRNAs on cell proliferation of U87 cells, 48 hours post transfection, was striking (~50% decrease in case of miR-
134 and ~75% decrease in case of miR-485) compared to normal cells. A comparison with scrambled transfection 
showed a statistically significant decrease in proliferation only for miR-485-5p.
BrdU assay revealed ~40% decrease in cell proliferation, upon overexpression of miR-485-5p in glioma cell 
line, compared to the scrambled, evident from the decreased S-phase population of cells upon miR-485-5p trans-
fection. The results for overexpression of miR-134 and combination (miR-134 + miR485-5p) were negligible.
We also observed a G2-M phase block after 24 hours of transfection of miR-485-5p, evident from increased 
G2-M population of cells (2 fold increase). When the cells were treated with a combination of both the miRNAs, 
a similar degree (2.2 fold) of G2-M phase arrest was noted [Fig. 5; Supplemental file].
Overexpression of key miRNAs make GBM cells pro-apoptotic. We found a substantial amount 
(from 45% in scrambled transfected cells to 31% in miR-134 transfected cells) of the cell population to be in the 
viable section for all the transfected conditions, and moderate changes in the total apoptotic cell population. 
However, there was ~1.4 fold higher cells in the early apoptotic section upon miR-134 overexpression, and a 
similar trend of 1.3 fold higher upon miR-485-5p transfection compared to scrambled transfection. The changes 
seen in the late apoptotic population of cells were very moderate.
Interestingly, when the cells were treated with a mixture of both the miRNAs, a marked increase (~2 fold) 
in total apoptotic cell population was observed, whereas the early apoptotic cell population was negligible in 
miR-overexpressed cells, compared to scrambled transfection [Fig. 6; Supplemental file]. This suggests the tumor 
suppressive potential of both of the miRNAs in GBM.
Figure 2. Sub-clusters within C14MC and CRISPR-induced activation of C14-IP-3. Panel A (i): Histogram 
showing >50 fold higher promoter activity (luciferase reporter) of internal promoter C14-IP-3 as compared to 
empty vector. Panel A (ii): Histogram showing ~15 fold higher enhancer activity (luciferase reporter) of internal 
promoter C14-IP-3 as compared to empty vector. X-axis represents the conditions (empty vector and vector 
with internal promoter), Y-axis shows Firefly/Renilla ratio. Panel B: CRISPR-induced up-regulation of C14-IP-3 
results in enhanced apoptosis of glioma cells. X-axis shows early and late apoptotic cell population. Y-axis shows 
the fold change of apoptotic population for all the transfection conditions, in comparison to control. The fold 
change was checked in two different cocktails of sgRNAs designed against C14-IP-3 (3 sgRNAs in each cocktail), 
in comparison to sg_GFP transfection. The variations within replicates is indicated by 5% error bars.
www.nature.com/scientificreports/
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Discussion
In glioblastoma, the higher-order, epigenetic regulatory components such as chromatin regulators, transcription 
factor alterations and non-coding genome aberrations play equally important roles in the tumorigenesis and 
progression of cancer22,23, as that of spontaneous somatic alterations and chronological selection for aggressive 
clones24,25. MicroRNAs, the most widely studied class of non-coding RNAs, have been reported to regulate var-
ious cellular and developmental processes26–28. Besides, deregulation of miRNAs is a common observation in 
numerous pathological conditions, including cancer, metabolic disorders, CNS disorders and cardiovascular dis-
eases29–31 - implicating their wide potential in therapeutic intervention.
Studies focussed on this miRNA cluster (C14MC; miR-379/miR-656 cluster) show its deregulation in various 
cancers, including gliomas11,12. In this study we show that C14MC downregulation is also consistent in other 
subtypes of diffuse astrocytic tumors. The median number of miRs downregulated in GBM was lower (60%) com-
pared to the lower grades (>85%), which are the early stages of glioma. A greater extent of downregulation in the 
Figure 3. Target validation of miR-134 and miR-485-5p. Panel A: Histogram showing luciferase reporter based 
miR-mRNA interaction of miR-134 with EGFR and RAF1. Panel B: Histogram showing luciferase reporter 
based miR-mRNA interaction of miR-485-5p with TP53, and negligible evidence of CDK6 interaction. X-axis 
represents the conditions (MES: miR mimic + empty vector + scrambled; MTS: miR mimic + target gene 
UTR + scrambled; MTI: miR mimic + target gene UTR + miR inhibitor), Y-axis shows Firefly/Renilla ratio. 
Error bars indicate standard error.
Figure 4. Invasion suppression by miR-134 and miR-485-5p. Histogram showing ~30% decrease of 
invasiveness upon miR-134 transfection. This effect is dramatically increased upon transfection of both miR-134 
and miR-485-5p, which resulted in ~50% decrease in invasion of glioma cells. X-axis represents the transfection 
conditions, Y-axis shows proportion of cell population. Variation in the triplicates is shown as 5% error bars.
www.nature.com/scientificreports/
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early stages indicated the downregulation to be an early event in the disease biology (Fig. 1), seen in both TCGA 
and in-house datasets. The systematic downregulation also indicates that one or more of the regulatory units for 
C14MC and cross-talks between them is altered in gliomas. This observation is also in agreement with an earlier 
report on another low grade glioma, medulloblastoma32. Patients with IDH mutations have been reported to have 
a better prognosis compared to those without such a mutation1. Interestingly, four C14MC miRNAs show higher 
expression in IDH-mutated GBM samples, suggestive of their prognostic value. Overall, higher expression of 
>60% of C14MC members was associated with better prognosis (survival) of GBM patients [Supplemental file]. 
We also used meta-expression of C14MC as a whole and found a significant association of higher expression with 
better survival [Panel C of Fig. 1]. Thus it was evident that a potentially better management of the disease is possi-
ble, if we can increase the level of expression for C14MC as a whole or for majority of its members.
Hierarchical interaction of imprinting control regions have been reported for the whole domain of 
Dlk1-Dio314, containing C14MC, but the probability of local regulation within C14MC was not attempted. We 
wanted to decipher the cis-regulators for C14MC further, to alter the state of multiple miRNAs simultaneously. 
As shown in supplemental file, we identified potential internal regulators by superimposing multiple layers of 
genetic and epigenetic information, as earlier reported by Ozsolak et al.33. The analysis indicated at least three 
different cis-regulatory regions within the genomic region of C14MC. We experimentally validated the presence 
of sub-clusters along with two internal cis-regulators within C14MC (Fig. 2A). Functional studies revealed varied 
potential of these regulators and we focused on the most potent cis-regulator (Fig. 2A) with 20 miRNAs down-
stream. The discovery of these internal cis-regulators is one of the most important findings of this study as this 
will allow selective modulation of sub-set of miRNAs, in turn modulate a pathway.
We utilised a CRISPR-cas9 based promoter induction system to test our hypothesis of altering the cancer-
ous phenotype of human GBM cells by increasing the expression of specific miRNAs. CRISPR mediated acti-
vation approaches have been reported to be efficient for gene activation in multiple reports34–36. Activation of 
C14-IP-3 using CRISPR-cas9 system resulted in increased expression of the specific miRNAs under its control 
Figure 5. G2-M arrest by miR-134 and miR-485-5p. Histogram showing 2 fold increase in G2-M population, 
with a ~40% decrease in S-phase cells upon miR-485-5p transfection. This effect is dramatically increased upon 
transfection of both miR-134 and miR-485-5p, which resulted in ~2.2 fold increase in G2-M phase cells. X-axis 
represents the transfection conditions, Y-axis shows proportion of cell population. Variation in the triplicates is 
shown as 5% error bars.
Figure 6. Apoptosis induction by miR-134 and miR-485-5p. Histogram showing ~1.5 fold increase in early 
apoptotic cell population upon either miR-134 or miR-485-5p transfection, and moderate increase in total 
apoptotic cell population. This effect is dramatically increased upon transfection of both miR-134 and miR-
485-5p, which resulted in ~2 fold increase in total apoptotic cell population, with not much change in early 
apoptotic cells. X-axis represents the transfection conditions, Y-axis shows proportion of cell population. 
Variation in the triplicates is shown as 5% error bars.
www.nature.com/scientificreports/
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and increased apoptosis of GBM cells (Fig. 2B). This is in direct agreement with our data on improved patient 
survival with increased miRNA expression for C14MC members.
We earlier reported a possible coordinated regulation of the ‘glioma’ pathway by members of C14MC (Fig. 1 
in17). Amongst various miRNAs, miR-134 (eight targets) and miR-485-5p (six targets) were predicted to target the 
maximum number of genes in the ‘glioma’ pathway17. These miRNAs were our natural choice to test as key miR-
NAs for their relevant multiple targets as well as for the fact that both of them were under the control of C14-IP-3, 
the most efficient internal promoter. MiR-134 is a brain-specific microRNA and already have proven roles in 
hippocampal neurons37 and also in differentiation of embryonic stem cells38. This miRNA has also been reported 
to inhibit epithelial to mesenchymal transition in lung cancers39, as well as identified as a metastasis inhibitor in 
hepatocellular carcinoma40. MiR-485-5p has been found to be differentially expressed in various cancers, includ-
ing leukemia41 and lung42 cancer. Thus these two miRNAs together are capable of targeting vital cellular processes 
like cytokine-cytokine receptor interaction, ErbB signalling, MAPK signalling, calcium signalling, mTOR signal-
ling and cell cycle regulation17, which are known to be dysregulated in GBM.
We validated EGFR and RAF1 as direct targets of miR-134 via luciferase assay. Recently, Forloni et al., showed 
that oncogenic EGFR blocks tumor suppressor genes, inhibiting TET1 in lung cancer and GBM43. RAFs are well 
studied oncogenes. They have been reported to be overexpressed in malignant gliomas44 and have thus been 
targeted for treatment45. Activated RAF/RAS pathway leads to activated AKTs, which have been reported to be 
essential for glioblastoma maintenance in vivo46. A recent report claimed that the combined blockage of Akt/
mTOR and MDM2 augments cell apoptosis and differentiation in GBM cancer stem cells47. Our finding of specific 
miRNAs targeting these molecules provides more ways of altering the gene expressions for a positive outcome.
TP53 was also validated to have direct interaction with miR-485-5p in this study. TP53 has been classically 
designated as the guardian of the cell, protecting it from uncontrolled growth, inducing DNA repair and apop-
tosis, in response to oncogenic stimuli48,49. But, evidences in recent literature suggest mutated TP53 promoting 
tumorigenesis50,51. Based on our results, miR-485-5p can have tumor-suppressor roles, by targeting and downreg-
ulating the mutant TP53, as the targeting region in the 3′-UTR is identical between the wild-type and the mutant.
Overexpression of these two miRNAs in glioma cells revealed blockage of cell invasion and proliferation, 
along with G2-M cell phase arrest, as well as increase in apoptotic cell population. When used in combination 
these effects were amplified. Thus, we propose that these two miRs should be considered for future therapeutics 
of GBM as they can tackle three characteristic features of glioblastoma namely, invasiveness, aggressive cell pro-
liferation and evasion of cell cycle arrest.
MicroRNA therapeutics as a field is emerging fast, enabling researchers and pharmaceutical companies across 
the globe to identify potential miRNAs and move onto preclinical and clinical stages of miRNA-based thera-
peutics. There have been reports of miRs inhibiting cell proliferation52,53 and inhibiting migration53,54 in various 
cancers. Our study thus becomes one of the first such studies in glioma to suggest novel cis-regulators for a very 
relevant set of miRNAs and also we recommend two specific miRNAs to be studied for their therapeutic poten-
tial. Furthermore, the key miRNAs, miR-134 and miR-485-5p show the tumor suppressive potential for GBM 
and reveal novel therapeutic potential for glioma. How these sub-clusters and their regulators are in cross-talk 
with the overall regulation of this imprinted region will be a very interesting question to be addressed in future 
research.
Materials and Methods
Cell Lines, Patient and Control tissue specimens. A total of 35 GBM (glioblastoma multiforme, Grade 
IV), 9 AA (anaplastic astrocytoma, Grade III), 15 DA (diffused astrocytoma, Grade II), and 10 control samples 
were taken for the study. All tumor samples were collected after informed consent was obtained in writing. All 
the methods followed in this study were in accordance with the Helsinki Declaration and the ethical board of All 
India Institute of Medical Sciences, Delhi, India approved all the methods included in the project. The control 
samples included in this study have been obtained from the NIMHANS brain bank, Bangalore, India, and include 
normal human corpus callosum tissues from road accident victims, without head injury. Fresh frozen samples 
were used for nucleic acid isolation. Flanking sections of the sample, measuring 5 micron were taken and stained 
by H&E for histological analysis. The histopathology of each collected specimen was reviewed to confirm ade-
quacy of the sample (i.e, minimum contamination of non-neoplastic elements) and to assess the extent of tumoral 
necrosis and cellularity. In vitro experiments were conducted on U87-MG cell line and LN229.
RNA Isolation and Expression profiling of C14MC (TLDA). The total RNA extraction for all the sam-
ples under discussion was done by miRVana miRNA isolation kit (Ambion), using the manufacturer’s protocol. 
The total RNA samples were processed further for cDNA conversion. Taqman assay for microRNAs was done 
using Taqman microRNA Reverse Transcription Kit (Life Technologies), followed by customized Taqman Low 
Density Arrays (TLDA) to quantitate the levels of 47 microRNAs from the chromosome 14 microRNA cluster, 
as per manufacturer’s protocol (we could find readily available assays for these miRs only). Quantitative PCR 
was conducted in a 10 µL volume on 7900HT Fast Real-Time PCR System. Ct values greater than 35 were con-
sidered as 35 for further analysis. The relative quantification was calculated by 2−∆∆Ct method21. Differentially 
expressed miRs were selected according to the fold change more than 2 (for up-regulation) and less than 0.6 (for 
down-regulation). Further details of the methodology are given in Supplemental file.
Survival analysis and association with IDH mutation from TCGA. Level 3 miRNA expression data 
and corresponding clinical information for GBM samples were taken from TCGA. Hazard curves for each 
miRNA were calculated using Kaplan-Meier survival function estimation method as implemented in Python 
package Lifelines. For calculation of survival function the samples were divided into two groups based on expres-
sion of the given miRNA. The partitioning were done such that samples with expression values above 80th 
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percentile were placed in one group and those below 20th percentile were placed in the other group. The signif-
icance of difference between survival functions of the two groups was assessed using log rank test. The samples 
with survival more than 730 days were censored. Plotting of hazard curves and their 95% confidence interval was 
done using custom Python scripts. Principal component analysis was performed using Python’s Scipy package.
IDH being the major classifier in the recent WHO classification, its association with C14MC expression was 
tested, to check for any significant difference of C14MC expression between IDH mutant and IDH wildtype GBM 
samples (n = 211; 13 mutant and 198 wildtype). Somatic variation datasets (level 3) were obtained from TCGA for 
IDH. This data was used for association testing with C14MC miRNA expression for the same samples (using level 
3 miRNA microarray expression data). Statistical significance for association between both datasets was tested 
using student’s t-test (assuming unequal variance), with a significance threshold of 0.05.
Prediction of local regulators. Epigenetic marks known for transcriptionally active regions (H3K4me1, 
H3K4me2, H3K4me3, H3K27ac, H3K9ac), and those known to be found in repressed regions (H3K27me3, 
H4K20me1) were checked in the NHA (normal human astrocytes). This data was superimposed with that of the 
contigs built from polyA+ RNA Seq data from HUVEC (method details given in Supplemental file), performed 
on nuclear fraction. The regions where the epigenetic marks and the breaks in contig overlapped were predicted 
to harbour potential regulatory role. All the data used were from ENCODE (GSE30567), and visualized in the 
UCSC Genome Browser (hg19).
Cloning of C14-IP3 and luciferase assay. Genomic DNA served as template for PCR amplification for the 
probable regulator, prior to cloning into pgl3-Basic and pgl3-Promoter plasmids (details given in Supplemental 
file). Glioma cell lines (U87-MG) were seeded in a 12-well plate using Lipofectamine 3000 (Invitrogen), using the 
manufacture’s protocol, when the cells reached a confluency of ~80%. 10 ng Renilla plasmid was used as the trans-
fection control. The ratio of Lipo to DNA used was 1:3 (1 ug DNA was used). The conditions used were lipo-only, 
empty vector, plasmid with the regulatory region inserted. Twenty-four hours post transfection, cells were washed 
twice with 1x PBS, and lysed with 80 µL of 1x passive lysis buffer (Promega), followed by the Dual luciferase 
reporter activity assay, according to the manufacturer’s protocol (Promega), using Infinite M200 (Tecan). Data 
was expressed as means ± standard errors of replicates.
CRISPR-Cas9 modulation of local regulator. The genomic sequence of C14-IP-3 was obtained from 
UCSC Genome Browser, and was subjected through sgRNA predicting software of CRISPRSCAN, with infor-
mation on human genome off-targets. A total of 10 sgRNAs could be designed against C14-IP-3. We have used 
a catalytically inactive form of Cas9 (dCas9) and fused it with an activating domain (VP64) to bring about the 
CRISPR activation (CRISPRa). As C14 miRNAs are downregulated in glioblastoma, CRISPRa approach was used 
to induce upregulation of C14-IP-3. This was attained by using two different cocktails, comprising of three sgR-
NAs each. Transfection of sgGFP was done, to serve as control. To assess the effect of this modulation, differen-
tial expression of randomly selected several miRNAs from the genome and the sub-cluster was studied. RNA 
isolation and Real time PCR protocol has been given in Supplemental file. Two different cocktails were chosen 
to assess the impact on cell phenotype (apoptosis) upon CRISPR-induced upregulation of C14-IP-3. Generation 
and purification of sgRNAs, and transfection details of CRIPSR-induced modulations are given in Supplemental 
file. The details of apoptosis assay can be found in subsequent methods section. The CRISPRa was done using 
Lipofectamine 3000 in glioma cells (LN229).
miR-mRNA interaction. As we earlier reported, miR-485-5p and miR-134 target important genes in the 
“glioma” pathway17. These two miRs from C14MC target the maximum number of genes in the pathway. Four 
predicted targets were taken for validation using luciferase assay in glioma cells (U87-MG), using 3′UTR clones 
from Genecopoeia (USA) and miR mimics from Dhermacon (GE-Dhermacon Inc., USA). The detailed method-
ology of the luciferase assay and subsequent relative expression of target genes upon miR overexpression has been 
given in the supplemental file.
Invasion assay. Glioma cells (~50,000) were seeded onto the matrigel chamber insert with serum free media, 
24 hours post transfection of the miRs. The BioCoat Matrigel plates used in the study were procured from BD 
Biosciences, and were of 24-well format. After 48 hours of miR mimic transfection, the media was removed from 
both the chambers. The inside of the upper chamber was gently wiped with 70% ethanol to remove any cell 
attached to the inner portion of the matrigel, followed by staining the chamber in 0.2% crystal violet, incubating it 
at room temperature for ~20 mins. The chambers were then washed with milliQ water and air dried for ~20 mins. 
After taking images of the stained chamber inserts, they were put in 1x cell lysis buffer for ~20 mins at room 
temperature, and protein absorbance was taken at 562 nm using Infinite M200 (Tecan). This assay was done in 
five replicates.
Proliferation assay. Proliferation assay was done using BrdU incorporation in glioma cells 48 hours post 
miRNA transfection. BrdU diluted to 1x (final conc. of 10 µM) in media was added to the cells 6 hours prior to 
completion of 24 hours of transfection. The cells were then harvested (via Accutase, Thermo Fischer Scientific) 
and the assay was performed using APC BrdU Flow kit (BD Pharmigen) as per the manufacturer’s protocol. The 
cells were analysed using BD FACSAria, acquiring 10,000 events per condition. The assay was done in triplicates. 
Four assay controls (untreated cells with no staining, all stained cells, BrdU untreated cells but with staining, 
BrdU treated cells but unstained with APC) were used to ensure the proper gating during analysis.
Apoptosis Assay. Annexin V (FITC labelled) and PI were (BD Pharmigen) used for this assay. Glioma cells 
transfected with miRNA mimics and inhibitors were harvested (via Accutase, Thermo Fischer Scientific) after 
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48 hours and subjected to the apoptosis assay as per the manufacturer’s protocol. The cells were analysed using 
BD FACSAria, acquiring 10,000 events per condition. The assay was done in triplicates. Apoptosis was induced in 
assay controls by treating cells with 0.1% H2O2. Four assay controls (untreated cells with no staining, treated cells 
stained with PI only, Annexin V only, and both) were used to ensure the proper gating during analysis.
Statistical Analysis. Wilcoxon test was used for significance testing of differential expression in different 
grades, using R statistical package. Kaplan-Meier analysis was performed using Scipy package in Python (details 
in Supplemental file). A significance level of p < 0.05 was considered significant for all the tests.
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